Page 4 - Bruce Cree News Today : Breaking News, Live Updates & Top Stories | Vimarsana

In a study of members of the Armed Forces, people who developed multiple sclerosis first had Epstein-Barr virus.

A new indirect comparison of three new FDA-approved treatment options for aquaporin4+ neuromyelitis optica has suggested that eculizumab is the most effective. But many limitations have been raised.

The new anti-CD20 monoclonal antibody showed significant improvement in the multiple sclerosis functional composite (MSFC) score, a measure of disability, compared with teriflunomide.

Treatment with Zeposia demonstrated a low annualized relapse rate of 0.103 and more than 70% of patients were relapse-free at four years Safety was consistent with prior findings and the established safety profile of Zeposia in up to 5 years of follow-up Bristol Myers Squibb today announced interim results from the Phase 3 open-label extension trial DAYBREAK, demonstrating the long-term efficacy and safety profile ...

Horizon Therapeutics: New Long-Term Data for UPLIZNA (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD) -- UPLIZNA continues to lower the rate of NMOSD attacks throughout the four-year open-label period (OLP) -- -- Results from NMOSD patient survey describe long and daunting journey to diagnosis -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new UPLIZNA (inebilizumab-cdon) data being presented at the American Academy of Neurology's 73rd Annual Meeting being held virtually April 17-22, 2021 (AAN 2021), including new, end-of-study data from the ...